NCT01378975View on ClinicalTrials.gov

A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases

PHASE2CompletedINTERVENTIONAL
Enrollment

146

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Malignant Melanoma
Interventions
DRUG

Vemurafenib

960 mg oral doses twice daily until disease progression, unacceptable toxicity or consent withdrawal.

Trial Locations (33)

2145

Wentworthville

3002

Melbourne

20133

Milan

24105

Kiel

28046

Madrid

31008

Pamplona

33075

Bordeaux

45122

Essen

48157

Münster

48201

Detroit

52621

Tel Litwinsky

53100

Siena

55905

Rochester

60596

Frankfurt

63110

St Louis

68167

Mannheim

72076

Tübingen

75006

Paris

75246

Dallas

75475

Paris

80045

Aurora

90025

Los Angeles

98195

Seattle

33612-9497

Tampa

02114

Boston

02215

Boston

28204-2839

Charlotte

M4N 3M5

Toronto

06202

Nice

1066 CX

Amsterdam

9713 GZ

Groningen

08036

Barcelona

HA6 2RN

Northwood

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01378975 - A Study of Vemurafenib in Metastatic Melanoma Participants With Brain Metastases | Biotech Hunter | Biotech Hunter